Viewing StudyNCT00266799

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-05 @ 12:11 PM
Last Modification Date: 2024-10-26 @ 9:21 AM
Study NCT ID: NCT00266799
Status: COMPLETED
Last Update Posted: 2017-06-08
First Post: 2005-12-15
Brief Title: The Efficacy and Safety of Pegylated Liposomal Doxorubicin Compared With Capecitabine as First Line Chemotherapy for Metastatic Breast Cancer P04445MK-2746-071
Sponsor: Merck Sharp Dohme LLC
Organization: Merck Sharp Dohme LLC
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Breast Cancer
Keywords: